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Abstract: Malignant gliomas are aggressive brain cancers. After many decades of 
intensive research they represent a major cause of cancer related mortality and morbidity.  
Management of malignant gliomas is very difficult. None of the current treatments are 
curative. High grade gliomas are optimally treated with surgery followed by radiotherapy 
and chemotherapy.  The impact of surgery on progression free survival and overall 
survival was a constant preoccupation and debate for decades among neurosurgeons. 
Different studies published in the last 25 years have provided evidence that the extent of 
resection of high grade gliomas can influence time to progression and median survival, 
although so far there is no class I prospective randomized trial to fully answer this 
question. Some of the most important studies are reviewed here. The modern 
neurosurgery relay on some tools that proved to be very helpful in guiding the surgeon 
to achieve the maximal tumoral cytoreduction with minimum impact on the brain’s 
eloquent areas. iMRI has been proved to be safe and became an important tool during 
tumor surgery, used alone or in conjuction with other important techniques: intra-
operative neurophysiology, awake cortical mapping, 5-ALA fluorescence etc. Although 
so far the prognostic of high grade gliomas is still disappointing, further understanding 
of the biology of these tumors and a patient-tailored treatment could be the keys of 
finding a cure in the future. 
 
Introduction 
Malignant gliomas are aggressive brain 
cancers. After many decades of intensive 
research high grade gliomas represent a major 
cause of cancer related mortality and 
morbidity. They are the most common primary 
brain tumors and account for about of 2% of 
all cancers.  [36, 23]. 
Due to the fact that glial cells undergo 
mitosis, they can present with abnormal 
proliferation, which may result in glial tumors. 
The origin of the tumor is thought to be a 
common pluripotent neuro-ectodermal 
precursor. This cell has the ability to 
differentiate along the astrocytic lineage, up to 
a grade IV. Primary glioblasomas are tumors 
that appear de novo [10]. 
The World Health Organization classifies 
the glial tumors into four grades. Grade I is 
reserved for special types of astrocytomas that 
are better delineated. The more typical 
astrocytic neoplasm is graded II through IV. 
There are some histological criteria that affect 
the prognosis like: cellularity, presence of 
giant cells, anaplasia, mitosis, vascular 
proliferation with or without endothelial 
proliferation, necrosis and pseudopalisading 
[42]. Grades III and IV are the malignant ones. 
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They represent approximately 70% of all 
gliomas and affect predominantly patients 
between 40 and 70 years [33]. Glioblasoma 
multiforme (grade IV) is the most aggressive 
primary brain tumor. Despite all the effort of 
trying to improve the treatment, the median 
survival is 12-15 months, with a 2 year 
survival rate of 15% up to 26% [49]. 
Currently there are no prevention strategies 
for malignant gliomas, except reducing the 
exposure of the head to high doses ionizing 
radiation. Among other studied risk factors 
supposed to be involved in the development of 
this type of brain tumors (radiation, chemical 
carcinogens, infection/ viruses) only radiation 
exposure has been established to be causal [35, 
58].  Some genetic syndromes, for exemple Li-
Fraumeni, are also more frequent associated 
with the development of malignant gliomas 
[35].   
Management of malignant gliomas is very 
difficult. None of the current treatments are 
curative [40]. Recent studies concentrate on 
understanding the molecular mechanism and 
gene mutation. Combined with clinical trials 
this work will be able to provide us a new 
promising and individual approach. Standard 
treatment consist of maximal surgical 
resection, radiotherapy and concomitant and 
adjuvant chemotherapy with temozolomide 
[43,15].  
Among all the treatment option available 
for malignant gliomas the surgery is the first 
step and maybe the most important one. 
Beside the fact that it provides tumoral tissue 
for pathological examination and reduces the 
tumor volume and edema, surgery also serve 
the purpose of treating the patient with BCNU 
implantable wafers and also developing in 
vitro drug sensitivity assay with the goal of 
predicting the clinical response to 
chemotherapy.   
Surgery - how much 
The first step in the treatment of malignant 
gliomas is the surgery. The mechanical 
cytoreduction of the tumor mass can help the 
patient to gain some time for other therapeutic 
intervention (radiotherapy, chemotherapy). 
The beneficial effect of tumor resection was 
observed both on cerebral blood flow and 
metabolism even at distant sites of the tumor. 
30 to 60 g of tumor mass will create a 
neurologic symptom while 100 g of tumor is 
lethal. A 90% resection of a 50 g (5X 1010 
cells) tumor theoretically reduces the tumor 
burden to 5 g (5 X 109 cells). After the total 
resection of the gadolinium enhancing regions 
on MRI 1 g of tumor (or 1X 109 cells) may be 
left in place. The other therapies are also 
involved in the tumor destruction: 
radiotherapy can kill two logs of cells while 
chemotherapy is believed to destroy one to two 
logs of cells. The body immune system will 
reduce the tumor burden to less than 1X105 
cells [32]. Although tumor cytoreduction 
appears to be vital, the presence of the viable 
tumor cells beyond the enhancing margins of 
the tumor- a cause for future recurrences- 
explain why surgery is more effective as part 
of multimodality treatment strategy [27,14]   
The impact of surgery of high grade 
gliomas on progression free survival and 
overall survival was a constant preoccupation 
and debate for decades among neurosurgeons. 
The infiltrative nature of these tumors makes 
impossible the curative resection. A wider 
margin resection coupled with adjuvant 
therapy creates the condition of delaying the 
recurrence and prolonging the survival [4]. 
An early retrospective study by Simpson et 
al [47] included 645 patients with 
glioblastoma from the Radiations Therapy 
Oncology Group database. The authors 
analyzed the survival with respect to known 
prognostic factors, such as age and Karnofsky 
Performance Status, as well as extent of 
surgery, site, and size. The median survival 
was 11.3 months in patients with complete 
resection, 10.4 months for partial resection and 
6.6 months for biopsy only. Some factors that 
offered survival benefit were identified: age 
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<40, Karnofsky Performance Score (KPS)>70, 
frontal lobe location and total resection. The 
conclusion of the study was that biopsy only 
yields inferior survival to more extensive 
surgery for patients with glioblastoma 
multiforme treated with surgery and radiation 
therapy.  
In 2003 Metcalfe and Grant, after the 
research of 2100 documents, were unable to 
draw a conclusion, due to the fact that they 
didn’t found enough randomized data for 
analysis. The authors underlined the idea that 
treatment must be considered on an individual 
basis. Although there was no good evidence 
that resection offers any clear advantage over 
biopsy, the indication of using biopsy for 
certain deep seated lesions is still standing,  
while small superficial placed frontal tumors 
can be resected  completely with little 
difficulty [34].   
Evaluation of the extent of resection and its 
influence on the survival using a 5- 
aminolevulinic acid- a non-fluorescent 
prodrug- was described by Stummer and al 
[50]. ALA is a precursor of haemoglobin that 
leads to the synthesis of porphyrins in 
malignant gliomas. The  intracellular 
accumulation of fluorescent porphyrins- 
which appear in red fluorescence under blue 
light- enable more complete resection of 
contrast- enhancing tumour.. 322 adult 
patients with radiographically suspected 
malignant gliomas were randomized, 
comparing cytoreductive surgery using ALA 
(n=161) versus conventional white light 
(n=161).  The authors concluded that surgery 
using 5-aminolevulinic acid enabled more 
complete resections of contrast-enhancing 
tumor. This was associated with a significant 
improvement in progression-free survival in 
patients with newly diagnosed malignant 
glioma undergoing cytoreductive surgery.  
One of the most comprehensive studies that 
attempt to find a correlation between the extent 
of the resection and survival comes from 
Lacroix et al [26]. 416 patients who underwent 
resection for glioblastoma over a period of 6 
years were included. The tumoral volume pre 
and postoperative was assessed using 
computer assisted image analyses. Five 
independent predictors of survival were 
identified by the authors following 
multivariate statistical analyses: age, 
Karnofsky Performance Scale (KPS) score, 
extent of resection, and the degree of necrosis 
and enhancement on preoperative MR imaging 
studies. When a resection of 98% or greater of 
the tumor was achieved a significant survival 
advantage was associated. The median 
survival was 13 months in patients with gross 
or near gross total resection (98% or greater) 
compared with 8.8 months for patients with 
less than 98% resection (p=0.02). A clinical 
outcome scale ranging from 0 to 5 was 
proposed based on age, KPS and radiographic 
evidence of necrosis. A significantly improved 
survival was observed in patients with lower 
scores (1-3) who underwent aggressive 
resections and a trend toward slightly longer 
survival was found in patients with higher 
scores (4-5). This study supports the concept 
of aggressive cytoreductive surgery as part of 
the management of high grade gliomas, yet not 
at the expense of neurologic function or 
surgical complications.  
Starting from almost 3 decades ago some 
authors suggested that partial tumor resection 
could be associated with a greater risk in terms 
of postoperative neurological worsening 
compared with radical resection or stereotactic 
biopsy.  Today is very well known that partial 
resection of glioblastoma carries significant 
risk of postoperative haemorrhage and edema- 
so called wounded glioma syndrome. In the 
series of Ciric et al [8] 42 patients with 
supratentorial gliomas were studied pre and 
postoperatively with CT scan. A gross total or 
nearly gross total resection was performed in 
the majority of patients (86%). The 
postoperative neurological status was stabile 
or improved in 97% of these patients.  40% of 
patients with partial resection presented a 
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neurological worsening after the operation. 
Fadul et al [13] examinated prospectively 
morbidity and mortality in 104 patients who 
underwent surgery for supratentorial gliomas. 
The authors reported that patients with 
complete resection had fewer acute neurologic 
complications and no greater risk of being 
neurologically impaired at 1 week compared 
with patients that were treated with biopsy or 
less extensive procedures. Another 
retrospective analysis   performed on 66 
patients- Vecht et al [55]- found that extensive 
surgery was correlated with a better immediate 
postoperative performance, a lower one-
month mortality rate and a longer survival in 
high grade gliomas. Because of the 
retrospective nature of the study the authors 
concluded that a more extensive surgery does 
not lead to more postoperative neurological 
deterioration.  Abrudan et al [1] published a 
study on 266 patients showing that age and 
type of surgery were prognostic factors that 
significantly influenced the survival at 12, 18 
and 24 months. The authors found that the 
global survival rate was 47 % at 12 months, 
26,3% at 18 months and 16,7% at 24 months 
and the difference of mean survival at 12, 18 
and 24 months monitoring was 2,8 months, 4,4 
months and 5,1 months respectively for the 
patients that underwent gross total resection of 
the tumor. This study adds a new argument in 
favor of maximal cytoreductive surgery 
whenever possible. 
Although the management of elderly 
patients with high grade gliomas is mainly 
focused on the optimal use of radiotherapy and 
chemotherapy, it is important first to address 
the patient to neurosurgical resection. Age and 
number and severity of additional illness are 
vital when considering the extent of resection 
in older patients, due to surgical risks and 
potential postoperative complication.  
There are some useful data regarding 
management of high grade gliomas in elderly 
patients, namely those over 65 years.   In the 
study of Vuorinen et al [56] 30 patients older 
than 65 years were randomized into two 
groups: stereotactic biopsy and open 
craniotomy and resection of the tumor. 
Ultimately only 23 tumors proved to be a 
malignant glioma (19 glioblasoma and 4 
anaplastic astrocytoma). 13 patients had a 
stereotactic biopsy and in 10 cases a resection 
was performed.   All the patients were referred 
to radiotherapy. The estimated median 
survival time was 85 days in the first group 
compared with 171 days in the second one. 
The estimated survival time was 2.757 longer 
after tumor resection. Radiotherapy had a 
significant effect on survival (p= 0.001). The 
authors didn’t find a significant difference in 
the time of deterioration between these two 
treatment (p=0.057) and concluded that in this 
population the survival was improved by the 
resection of the tumor although the overall 
benefit is modest [56].  
  In 2010  Chaichana et al [7] reported a 
retrospective study were they found that 
patients who underwent surgical resection had 
median survival of 5.7 months, while patients 
who underwent needle biopsy without 
resection had median survival of 4.0 months. 
For patients aged 70 years and older  median 
survival was 4.5 months for 26 patients with 
surgical resection as compared with 3.0 
months for 26 patients who underwent needle 
biopsy (P = 0.03). The authors found no 
significant differences in postoperative 
outcomes among the two groups. As a 
conclusion this study demonstrates that older 
patients tolerate aggressive surgery without 
increased surgery-related morbidity and have 
prolonged survival as compared with similar 
patients undergoing needle biopsy. 
A study of Zouaoui et al [59] in 2014 
describes oncological patterns of care, 
prognostic factors, and survival for patients 
with glioblastoma multiforme older than 70 
years in France. 265 patients were included. 95 
of them underwent surgical resection and 107 
biopsy. Adjuvant therapy was also performed- 
chemotherapy alone (CT), radiotherapy alone 
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(RT) or concomitant radiochemotherapy 
(CRC). In the group of patients with biopsy 
median survival was 199 days in those who 
received only CT, 318 days in those who 
received CRC and 149 days in patients who 
received RT. In the group of patients that 
underwent surgical resection the median 
survival (in days) was as following: 245 with 
CT, 372 with CRC and 26 with RT.   A 
hypothesis of the authors was that elderly 
patients are undertreated. The authors 
concluded that Karnofsky performance status 
seems to be the most relevant clinical 
predictive factor and RS and CRC have a 
positive impact on survival for elderly GBM 
patients in the general population, at least 
when feasible. 
Mariniello et al [31] compared the effects 
of combined treatments (surgery and 
radiochemotherapy) on the outcome and 
survival between elderly (≥ 65 years) patients 
with glioblastoma and younger ones (<65 
years). The median survival of older patients 
was 14.5 months, significantly lower than 
patients < 65 years (17 months) (p = 0.02). The 
conclusion of the study was that when several 
criteria of selection to surgery are respected 
(good Karnofsky performance status (KPS), 
largely resecable tumor, and no significant co 
morbidity) the difference of survival is less 
significant.   
Age is one of the most important 
prognostic factor in patients diagnosed with 
malignant gliomas. A study of Uzuka et al [54] 
suggested that postoperative KPS score is an 
important prognostic factor for glioblastoma 
patients aged ≥ 76 years. Based on statistical 
analyses of 79 glioblastoma patients aged  ≥ 76 
years (median age 78.0 years; 34 men and 45 
women) that were treated with tumor resection 
or biopsy followed by chemotherapy or 
radiotherapy,  the authors reported a median 
overall progression free survival of 6.8 months 
and a median overall survival of 9.8 months. 
Patients aged ≥ 78 years were significantly less 
likely to receive radiotherapy (p = 0.004) and 
patients with a postoperative KPS score of ≥ 
60 were significantly more likely to receive 
maintenance chemotherapy (p = 0.008). Two 
independent prognostic factors were 
identified: postoperative KPS score ≥ 60 ( p = 
0.017) and temozolomide therapy  (p < 0.001) 
Konqlund et al [24] included in their study 
80 patients over 60 years old diagnosed with 
high grade gliomas and operated at Oslo and 
Haukeland University Hospitals between 
2008-2009. Clinical outcome was assessed at 
six months and overall mortality at 2 years. 
Surgical morbidity included neurological 
sequels (10%), postoperative hematomas 
(3.8%), hydrocephalus (1.3%) while the 
surgical mortality reported was 1.3%. Median 
overall survival was 8.4 months. Adjuvant 
radiochemotherapy increased significantly the 
survival. In univariate analyses couple of 
factors were identified to reduce survival: age 
≥ 80 years, subtotal resection, American 
Society of Anesthesiology (ASA) scores 3-4, 
Karnofsky performance scale (KPS) < 70, and 
mini-mental state examination (MMSE) score 
< 25. Authors conclusions were that surgical 
treatment of high grade gliomas carries low 
mortality and acceptable morbidity in patients 
aged ≥ 60 years and maximum tumor resection 
should be attempted.   
The benefit of total tumor resection in 
elderly patients is supported by others studies 
in the literature. After analyzing 437 patients  
≥70 years  Scott et all [45] identified 4 
prognostic subgroups with markedly different 
median survivals: subgroup I =patients <75.5 
years of age who underwent surgical resection 
(9.3 months); subgroup II = patients ≥75.5 
years of age who underwent surgical resection 
(6.4 months); subgroup III = patients with 
Karnofsky performance status of 70 to 100 
who underwent biopsy only (4.6 months); and 
subgroup IV = patients with Karnofsky 
performance status <70 who underwent biopsy 
only (2.3 months). Grossman et al [17] 
published a study aiming to compare surgical 
outcome of elderly patients undergoing 
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awake-craniotomy to that of younger patients. 
A total of 334 young (45.4 ± 13.2 years, mean 
± SD) and 90 elderly (71.7 ± 5.1 years) 
patients were studied. The authors found no 
significantly higher rate of mortality, or 
complications in the elderly group and 
concluded that gross total tumor resection in 
elderly patients with high grade was associated 
with prolonged survival. Gulti et al [18] 
explored the survival and treatment provided 
to elderly patients diagnosed with 
glioblastoma in a population-based setting, 
from the Norwegian Cancer Registry.  2882 
patients who were diagnosed with 
glioblastoma between 1988 and 2008 were 
included. The following factors were 
identified as independent predictors of reduced 
survival: increasing age, no tumor resection, 
no radiotherapy, and no chemotherapy. In the 
authors opinion despite multimodal treatment 
the gain for the oldest seems at best very 
modest and the prognosis remains very poor. 
Another study published in 2012 
underlines the importance of total resection 
regardless of age. Oszvalt et al [37] collected 
data from 361 patients with newly diagnosed 
cerebral glioblastoma. Depending on tumor 
size, location and Karnofski Performance 
Scale score the patients underwent resection 
(complete, subtotal and partial) or biopsy. 
After the surgery all the patients received 
adjuvant treatment.  The overall survival of 
elderly patients (>65 years) (9.1 ± 11.6 
months) was significantly lower than that of 
younger patients (<65 years) (14.9 ± 16.7 
months; p = 0.0001). Age was a negative 
prognostic factor in patients undergoing 
biopsy (4.0 ± 7.1 vs 7.9 ± 8.7 months; p = 
0.007), but not in patients undergoing tumor 
resection (13.0 ± 8.5 vs 13.3 ± 14.5 months; p 
= 0.86), which lead the authors to conclude 
that   resection should not be withheld from 
patients only on the basis of age.  
One of the most extensive study comparing 
biopsy, partial resection and gross total 
resection in older patients was published by 
Almenawer et al at the beginning of this year 
[2]. The authors undertook a meta-analysis of 
the outcome, overall survival (OS), 
postoperative Karnofsky Performance Status 
(KPS), progression-free survival (PFS), 
mortality, and morbidity in patients over 60 
years old after the surgical procedure. 12607 
participants from 34 studies were included. 
When comparing the tumor resection (of any 
extent) with biopsy overall survival (MD 3.88 
mo, P < .001), postoperative KPS (MD 10.4, P 
< .001), progression free survival (MD 2.44 
mo, P < .001), mortality (RR = 0.27, P = .002), 
and morbidity (RR = 0.82, P = .514) were in 
favor of the resection group. Gross total 
resection was found to be superior to subtotal 
resection in terms of overall survival (MD 3.77 
mo, P < .001), postoperative KPS (MD 4.91 
mo, P = .016), and progression free survival 
(MD 2.21 mo, P < .001) with no difference in 
mortality (RR = 0.53, 95% CI: 0.05-5.71, P = 
.600) or morbidity (RR = 0.52, 95% CI: 0.18-
1.49, P = .223).  These findings support the 
idea of increasing extent of safe resection in 
elderly patients, which can lead to an upward 
improvement in survival time, functional 
recovery, and tumor recurrence rate at this 
group of age (>60 years). 
Recurrent glioma resection has also been 
debated in the literature and there are many 
class III studies that show the improvement of 
survival with re-resection. A study of 
Rostomily et al [41] was focused on 51 adult 
patients with recurrent malignant gliomas that 
were treated in a Phase II trial of multidrug 
chemotherapy. 31 patients underwent radical 
tumor resection before chemotherapy. Higher 
Karnofsky scores, lower grade initial 
histology, lack of prior chemotherapy, greater 
degree of myelotoxicity, smaller postoperative 
tumor volumes, greater extent of surgical 
resection, and a local versus diffuse recurrence 
pattern were associated with a longer overall 
median time to tumor progression. The overall 
median survival time was increased in patients 
with higher Karnofsky scores, lower grade 
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histology at the time of recurrence, greater 
degree of myelotoxicity and lobar versus deep 
tumor location. Helseth et al [19], after 
studying 516 patients with glioblastoma who 
underwent primary surgery in 2003-2008 
found an overall survival (OS) of 9.9 months 
and negative prognostic factors like increasing 
age, poor neurological function, bilateral 
tumor involvement, biopsy instead of 
resection, and radiotherapy alone compared to 
temozolomide chemoradiotherapy. The 
authors concluded that in a carefully selected 
group of patients, repeat surgery significantly 
prolongs OS. Park et al [38] based on clinical 
and radiographic data of 34 patients who 
underwent re-operation of recurrent GBM 
tumors validated a preoperative scale that 
identifies patients likely to have poor, 
intermediate, and good relative outcomes after 
surgical resection. The authors found that the 
factors associated with poor postoperative 
survival were: tumor involvement of 
prespecified eloquent/critical brain regions (P 
= .021), Karnofsky performance status (KPS) 
< or = 80 (P = .030), and tumor volume > or = 
50 cm (3) (P = .048). Sughrue et al [53] 
published a paper where they showed that 
repeat surgery for glioblastoma is beneficial in 
many cases providing the patient with a 
satisfying disease free period but is difficult to 
reliably predict who these patients are. 
Useful tools in the surgical treatment of 
high grade gliomas 
The use of intra operative fluorescence in 
gliomas surgery is a recent innovation. In 
living mammalian cells 5-ALA is a natural 
biochemical precursor for heme synthesis 
[12]. Each cell metabolizes 5-ALA along a set 
pathway toward heme production. The 
synthesis of the endogenous fluorescent 
molecule, protoporphyrin IX (PpIX), is 
induced through metabolic conversion in the 
mitochondria [5]. Given via oral route 5 ALA 
does not usually cross the intact blood-brain 
barrier but it can easily pass through the 
disrupted BBB found in gliomas [51]. The 
principle is simple: 5-ALA acts as a diagnostic 
fluorescent marker; given orally it assists the 
surgeons to visualize directly the extent of 
tumor resection when lighting up the operative 
field with a specific wavelength light source. 
The tumor cells that accumulates PpIX can be 
easily discerned from the surrounding normal 
cell. The fluorescent dye peak is 2-6 hours 
after oral administration and disappears from 
the tumor tissue after 12 hours [28]. 
  5-ALA mediated-photodynamic therapy 
(5 ALA mediated PDT) has revealed a 
promising adjuvant tool in the treatment of 
malignant gliomas [43]. The rapid PDT 
response in vivo is due to three types of 
mechanisms: 1. PDT can directly damage and 
kill the cancer cells; 2. alteration of the tumoral 
blood flow: stasis, vascullar collapse/ leakage; 
3. the induction of an inflammatory response 
due to the release of cytokines and other 
inflammatory mediators from target cells [30]. 
Other studies have shown that 5–ALA PDT 
causes mitochondrial and nuclear DNA 
damage with cytochrome c release and 
activation of caspase-3 and caspase-9 in 
glioma cells [22]. The lack of randomized 
controlled trials and an optimal 5-ALA-PDT 
regimen may be the reason why 5-ALA-PDT 
is not a standard treatment for malignant 
gliomas. Some challenging side effects that 
neurosurgeons have to deal with are cerebral 
edema and long-lasting skin photosensitivity. 
5-ALA- PDT could be regarded as a promising 
alternative in glioma treatment if the 
specificity and selectivity of 5-ALA-PDT in 
glioma tissue would be improved [28]. 
  Hirschberg et al [21] evaluated the effects 
of 5-aminolevulinic acid (ALA)-mediated 
photodynamic therapy (PDT) on the 
invasiveness of human glioma cells migrating 
from implanted multicell human tumor 
spheroids. The authors found that 5-ALA 
mediated PDT inhibited the invasiveness of 
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the gliomal cells by a migratory inhibition 
effect rather than by a cytotoxic one 
  A study of Puppa et al [9] showed that 5-
ALA guided resection of high grade gliomas 
permits an overall gross total resection of 90% 
in 100% of patients, and 98% in 93% of 
patients. In the same study the authors found 
that in 43% of patients the boundaries of 
fluorescent tissue exceeded those of tumoral 
tissue detected by neuronavigation and 
concluded that 5-ALA fluorescence in the 
surgery of high grade gliomas enables a gross 
total resection in 100% of cases even if 
selection of patients remains a main bias.  
Stummer et al [52] published a study where 
they showed that fluorescence appears 
superior to contrast enhancement on MRI for 
indicating residual tumor.  A systemic review 
and meta-analysis of 10 studies from the 
literature made by Zhao et al [58] showed a 
level 2 evidence of superior efficiency of 
fluorescence guided resection to 
neuronavigation guided surgery with respect 
to diagnostic accuracy, extent of tumor 
resection, safety and survival. Finally, a study 
of Slof et al [48] showed that 5-ALA guided 
resection is a cost effective option for the 
treatment of high grade gliomas.  
Intra operative MRI (iMRI) is an imaging 
tool used primarily to increase the extent of 
tumour resection (EOTR) while minimizing 
the impact of the surgery on the brain’s 
eloquent areas. With stereotactic frameless 
neuro-navigation, iMRI shows changes 
occuring in the brain as the resection goes on. 
This is very important as changes occur during 
the resection: brain shift diminishes, the effect 
of gravity may be different than on the pre-op 
scans, etc. Those factors render the 
“conventional” navigation inaccurate and the 
extent of resection may suffer from it. A 
review by Liang and Schulder [29] showed 
that iMRI enabled a significant increase of 
EOTR, and was a safe tool used in 
combination with other techniques such as 
intra-operative neurophysiology, awake 
cortical mapping, 5-ALA fluorescence, etc. for 
the treatment of high grade gliomas. The same 
ideea is supporterd by Schatlo et al [44] in a 
recent article focusing on the impact of gross 
total resection on progression and survival in 
patients with high-grade glioma and how this 
can be achieved using iMRI in combination 
with 5-ALA.  Although some studies like the 
one published by Senft et al [46] showed 
evidence supporting the use of the technology 
in gliomas, other studies seem to disapprove 
this use or at least to show its limits. It is the 
case of Kubben et al [25] which states that 
there is, at best, a level 2 evidence to support 
the use of this technology compared with 
conventional neuronavigation-guided surgery 
in increasing EOTR, enhancing quality of life, 
or prolonging survival after resection of 
glioblastoma multiforme. On the other side 
iMRI is an extremely expensive technology 
and require the upgrading of the operating 
room, thus inducing a huge cost to the health 
system.  
Intra operative mapping is a technique 
which aims to delimitate the tumoral margins 
and thus to limitate the resection to non 
eloquent tissues. It is of great importance 
because of the infiltrative nature of gliomas, 
where these lesions not only grow but also 
migrate along white matter tracts. This 
technique helps maximize the extent of tumor 
resection while minimizing postsurgical 
morbidity, in order to increase the median 
survival as well as to preserve quality of life 
[11]. A review from Garrett et al [16] shows 
the utility of this technique in the resection of 
gliomas in eloquent brain regions. Another 
study of Hervey-Jumper SL et al [20] analyzed 
retrospectively a single surgeon experience on 
859 patients undergoing awake brain tumor 
surgery between 1986 and 2014. Perioperative 
risk factors like ASA classification, body mass 
index, smoking status, psychiatric or 
emotional history, seizure frequency and 
duration and tumor site, size, and pathology 
were assessed. The overall perioperative 
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complication rate was 10% and the authors 
concluded that awake brain tumor surgery can 
be safely performed with extremely low 
complication and failure rates. Brown et al [6] 
found that awake craniotomy results in a 
shorter hospital stay and less frequent 
postoperative deficits compared with general 
anesthesia. The data collected retrospectively 
from 1970 until 2012 suggests an expanded 
role for awake craniotomy in brain tumor 
surgery regardless of tumor location. 
Different techniques used for functional 
mapping of the brain have largely replaced  
invasive techniques such as awake craniotomy 
[39]. Non invasive evaluation of the brain 
include BOLD-functional MRI (fMRI) 
magnetoencephalography (MEG), and 
transcranial magnetic stimulation (TMS). A 
case study by Asim F. Choudri et al [3] 
showed that tri-modality functional brain 
mapping allows non-invasive localization of 
motor, sensory, and language centers as well 
as white matter pathways helping the surgical 
planning.  
Conclusions 
After three decades of intensive research 
the prognosis for patients with HGGs is still 
disappointing. The infiltrative nature of these 
cancers precludes a surgical cure but 
nevertheless surgery remains the first and 
more important step for achieving a good 
quality of life.  Different studies published in 
the last 25 years have provided evidence that 
the extent of resection of high grade gliomas 
can influence time to progression and median 
survival, although so far there is no class I 
prospective randomized trial to fully answer 
this question. A maximal resection is preferred 
but not with any cost.  
The standard of care for elderly patients 
with high grade gliomas remains controversial 
and undefined. Although high grade gliomas 
can develop at any age, elderly population 
represents half of the glioblastoma population. 
The increasing age remains the most powerful 
negative prognostic factor in high grade 
gliomas, being related with less favorable 
tumor biology, less aggressive care and co 
morbid disease  
In order to achieve a maximum resection 
current concept of surgical decision-making 
takes in consideration multimodal pre and 
intraoperative information. iMRI has been 
proved to be safe and became an important 
tool during tumor surgery. Used in conjuction 
with other important techniques, such as intra-
operative neurophysiology, awake cortical 
mapping, 5-ALA fluorescence etc., iMRI can 
help the surgeon to obtain the highest levels of 
tumor resection while minimizing neurologic 
injury. 
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